Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 936 of 6351
-
MRI-Guided therapy could spare rectal cancer patients from unnecessary surgery
Disease control Recruiting nowLocally advanced rectal carcinoma raise the issue of both the oncological control, local and general, and the therapeutic morbidity. Surgery alone can cure only one out of two patients, radiochemotherapy improves the local control but the metastatic risk remains about 30% with en…
Phase 2/3 • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New COVID vaccine shows promise in both needle and nasal spray forms
Vaccine CompletedThis is a Phase II study with single-blinded safety phase followed by double-blinded randomization, placebo-controlled, of administration of a single dose by two different administration routes (intramuscular route or intranasal route), to evaluate immunogenicity and safety of th…
Phase 2 • Sponsor: Laboratorio Avi-Mex, S.A. de C.V. • Aim: Vaccine
Last updated Jun 27, 2026 07:52 UTC
-
New combo therapy offers hope for hard-to-treat GI cancers
Disease control OngoingThis Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients. The fixed-dose Expansion phase will be conducted at the recommended dose for expa…
Phase 1/2 • Sponsor: Rottapharm Biotech • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Heart drug trial aims to cut deadly attacks
Disease control OngoingStudy CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Blood test may predict rapid kidney decline in diabetes
Diagnosis OngoingThe current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
Sponsor: Renalytix AI, Inc. • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Race against time: can speedy hip surgery save more lives?
Disease control Recruiting nowThe HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The…
Sponsor: Population Health Research Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New study matches melanoma patients to drugs based on their Tumor's genes
Disease control CompletedThis is a patient oriented translational research project aiming to improve clinical outcomes for patients with BRAF and NRAS wild-type unresectable Stage III or Stage IV metastatic melanoma who have progressed on, or are unable to receive standard therapy (in general, immunother…
Phase 2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Lung cancer vaccine shows promise in early prevention trial
Prevention CompletedThis early phase I trial studies the side effects of a vaccine called CIMAvax-EGF and to see how well it works in preventing lung cancer from developing in patients at high risk for lung cancer or coming back (recurrence) in stage IB-IIIA non-small cell lung cancer survivors. In …
Early phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
Could a common antibiotic ease severe wheezing in young children?
Disease control Stopped earlyAZ-SWED is a parallel group, double blind, placebo control efficacy clinical trial with two separate hypotheses. The trial compared the 5-day outcome of preschool children presenting to an Emergency Department (ED) with an acute, severe wheezing episode and treated with either on…
Phase 3 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Heart transplant monitoring may go needle-free with new MRI technique
Diagnosis Recruiting nowHeart transplantation (HTx) is a well-established life-saving procedure but is associated with severe complications. Regular monitoring of heart transplant recipients is thus important for the early detection of these complications. Current standard clinical tests, however, rely …
Sponsor: Northwestern University • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
New hope for NF1 patients: drug trial targets painful tumors
Disease control OngoingA global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
One shot to rule them all? new combo meningitis vaccine tested in teens
Vaccine OngoingThe purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 12:06 UTC
-
New hope for BRCA-Linked breast cancer: targeted drug talazoparib under study
Disease control Recruiting nowThis research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail shows promise for lung cancer patients with brain tumors
Disease control OngoingThis is an open-label, non-randomised, phase II, multicenter clinical trial. 71 stage IV or recurrent, non-small cell lung cancer patients with synchronous brain metastases will be enrolled in this trial to evaluate the efficacy of Nivolumab plus Ipilimumab plus two cycles of pl…
Phase 2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can an AI spot hidden heart disease that doctors miss?
Diagnosis Recruiting nowDespite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine. Recent advance…
Sponsor: Cedars-Sinai Medical Center • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
Heart shield after COVID: new trial tests exercise and meds to stop heart failure
Prevention Recruiting nowThis is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors \>50 years old. The overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in C…
Sponsor: Baker Heart and Diabetes Institute • Aim: Prevention
Last updated Jun 27, 2026 07:53 UTC
-
Could a walk a day keep brain fog away after a stem cell transplant?
Symptom relief Recruiting nowCancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Age is a risk fac…
Sponsor: University of Nebraska • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
New pill aims to stop MS relapses in its tracks
Disease control OngoingMulti-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Phase 3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy aims to control hard-to-treat myeloma
Disease control OngoingSelinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based combination in RRMM selected by ph…
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Texting parents could be key to curbing HPV-Related cancers
Prevention CompletedThis study will test the effectiveness of two interventions (parent-targeted text messages and a brief clinician-targeted training) at increasing HPV vaccination among 11- to 12-year-olds living in Florida.
Sponsor: University of Florida • Aim: Prevention
Last updated Aug 06, 2026 00:00 UTC